EyePoint Pharmaceuticals is a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, with two commercialized products for serious eye diseases that can lead to blindness and an impressive pipeline of drugs to treat serious retinal diseases. Nancy, a veteran in the biopharmaceutical industry, joined EyePoint in September 2016 as President and Chief Executive Officer and is a member of the company’s Board of Directors.in 2023 she then semi-retired and became Executive Vice Chair of EyePoint. EyePoint has grown substantially under Ms. Lurker’s leadership, taking it from a small, research driven organization to one having several marketed ophthalmology products and a leading pipeline of extended delivery treatments for serious retinal diseases. Ms. Lurker has more than 30 years of experience in the pharmaceutical and pharmaceutical services industries. Prior to joining EyePoint, Ms. Lurker was President and CEO at PDI a leading commercialization and contract sales company that commercialized hundreds of pharmaceutical drugs, devices, OTC and diagnostic tests in collaboration with their business partners through PDI’s 1100 sales representatives. In 2015, Nancy led the sale of PDI’s contract sales division to Publicis Touchpoint Solutions.
Prior to joining PDI, she was Senior Vice President and Chief Marketing Officer for Novartis Pharmaceuticals Corporation where she oversaw a $6 billion product portfolio in multiple therapeutic areas, including cardiovascular, CNS, respiratory and anti-infectives.
Ms. Lurker was also President and CEO of ImpactRx, a private equity backed market research firm servicing the biopharmaceutical industry. Prior to ImpactRx she was Group Vice President – Global Primary Care Products for Pharmacia Corporation, and a member of Pharmacia’s US Executive Management Committee.. She began her career at Bristol Myers Squibb, where she quickly rose from Senior Medical Representative to Senior Director of Worldwide Cardiovascular Franchise Management where she oversaw the global launch of Plavix, along with many other successful drug launches.
Ms. Lurker graduated magna cum laude with a BS in biology from Seattle Pacific University, and holds an MBA from the University of Evansville (Evansville, IN).
In addition to her Board Director role at EyePoint Pharmaceuticals, Nancy also serves on the Board of Altasciences, LLC, a rapidly growing, private, contract research organization (CRO) focused on early stage drug development services. She is also a Board member of National Sanitation Foundation, a not for profit focused on improving the quality of water, food and human health. Ms. Lurker is a member of the Novo Advisory Group, which advises on large investments for the $200 Billion private equity fund of Novo A/S, Denmark. She is also a member of Stanford’s M-TRAM program (Masters in Translational Medicine).
Ms. Lurker has also served on multiple other public and private Boards over her career, including Cancer Treatment Centers of America, a multi-billion-dollar private cancer treatment hospital system, Aquestive Therapeutics, a public, CNS commercial stage company, and Auxillium Pharmaceuticals, among others.